A Phase I Single Ascending Dose (SAD) Trial of SNDX-6352 Assessing the Safety, Pharmacokinetics and Pharmacodynamics of the Anti-CSF-1R Monoclonal Antibody (SNDX-6352) in Healthy Volunteers

Trial Profile

A Phase I Single Ascending Dose (SAD) Trial of SNDX-6352 Assessing the Safety, Pharmacokinetics and Pharmacodynamics of the Anti-CSF-1R Monoclonal Antibody (SNDX-6352) in Healthy Volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2017

At a glance

  • Drugs UCB 6352 (Primary)
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 11 Nov 2017 According to a Syndax Pharmaceuticals media release, data from this trial were presented at the Society of Immunotherapy of Cancer (SITC) Annual Scientific Meeting
    • 11 Nov 2017 Results published in the Syndax Pharmaceuticals Media Release
    • 07 Nov 2017 According to a Syndax Pharmaceuticals media release, data from this trial will be presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top